Navigation Links
Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S.
Date:9/23/2010

 In two Phase 2 clinical trials, bardoxolone significantly improved kidney function in patients with advanced CKD and Type 2 diabetes.  CKD currently affects more than 50 million adults worldwide, and the number of patients is rapidly increasing throughout the world.

"Reata is very pleased to have Abbott as our partner and believe that its existing renal capabilities will be a great asset to the global program," said Warren Huff, chief executive officer of Reata.  "This partnership allows us to meet our strategic goal of establishing our own commercial presence in the U.S. and building a sustainable, fully integrated pharmaceutical company."

This transaction does not impact Abbott's previously issued ongoing earnings-per-share guidance for 2010.  Abbott expects to incur one-time specified items in the fourth quarter of 2010, primarily related to in-process research and development.

About Bardoxolone MethylBardoxolone methyl is an antioxidant inflammation modulator (AIM) that activates Nrf2, thereby inducing the transcription of more than 250 genes that decrease the level of oxidative stress and suppress several inflammatory mediators.  In two Phase 2a studies, bardoxolone methyl was shown to produce a statistically significant increase in estimated glomerular filtration rate as well as improvements in other key markers of renal function in Stage 3b and 4 CKD patients with Type 2 diabetes.

About Chronic Kidney Disease and Diabetic Kidney Disease (Nephropathy)CKD is a highly prevalent condition, affecting more than 50 million adults around the world.  Half of CKD patients also have diabetes, a percentage that is expected to grow as rates of diabetes increase.  Diabetes is the leading cause of CKD, with as many as 30 to 40 percent of Type 2 diabetics developing the disease.  Available therapies modestly slow the progression of CKD, and patients ultimately progress to dialysis.

About
'/>"/>

SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
2. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
3. Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis
4. Abbotts ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
5. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
6. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
7. Abbotts m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award
8. Abbotts HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
9. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
10. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
11. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... , April 17, 2015 ... EGFR mutation   is a viable alternative to tumour biopsy ... testing in all patients with advanced NSCLC   ... effectiveness of plasma circulating tumour DNA (ctDNA) testing for epidermal ... with advanced non-small cell lung cancer (NSCLC) in clinical practice. ...
(Date:4/17/2015)... , Apr. 17, 2015 Research and Markets ... of the "Mammography Equipment - Global Strategic Business ... report analyzes the worldwide markets for Mammography Equipment in ... Equipment, and Digital Mammography Equipment. The report provides separate ... , Japan , Europe ...
(Date:4/17/2015)... , Apr. 17, 2015 Steven Rash ... ALGA ), and its operating subsidiary American Seed & ... exclusive presentation to investors yesterday in New York City.  ... The American Seed & Oil Company has ... Hippie Butter Hemp Seed Foods , the ...
Breaking Medicine Technology:"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 2"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 3"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 4Mammography Equipment (Analog & Digital) Market 2015-2020 - Global Strategic Business Report: Breast Imaging Screening Programs Push Sales 2American Seed & Oil Company Benchmarks its Consumer Product Development Strategy Against Proctor & Gamble 2American Seed & Oil Company Benchmarks its Consumer Product Development Strategy Against Proctor & Gamble 3
... insight for physicians, NATICK, Mass. and WASHINGTON, ... ) today announced results from an analysis,of the ... by the,Cardiovascular Research Foundation (CRF) with research grant ... MDCO ) is designed to,determine the safety ...
... Receives Regulatory Clearance to Begin Phase I,Clinical Trial, ... (Nasdaq:,INSM), a developer of follow-on biologics and biopharmaceuticals, ... United Kingdom,s Medicines,and Healthcare products Regulatory Agency (MHRA) ... Company,s second follow-on biologic (FOB) product,candidate, INS-20. Insmed,s ...
Cached Medicine Technology:HORIZONS AMI Trial Demonstrates Superior Outcomes with TAXUS(R) Drug-Eluting Stents in Heart Attack Patients 2HORIZONS AMI Trial Demonstrates Superior Outcomes with TAXUS(R) Drug-Eluting Stents in Heart Attack Patients 3HORIZONS AMI Trial Demonstrates Superior Outcomes with TAXUS(R) Drug-Eluting Stents in Heart Attack Patients 4Insmed Initiates Clinical Study for Follow-on Biologic Version of Neulasta(R) 2Insmed Initiates Clinical Study for Follow-on Biologic Version of Neulasta(R) 3Insmed Initiates Clinical Study for Follow-on Biologic Version of Neulasta(R) 4
(Date:4/18/2015)... 18, 2015 Carinsurancesavings.biz has released a ... are cheaper during Spring. , Spring can ... plan. Drivers should make sure they compare the newest ... Clients can learn more about Spring car insurance offers ... Auto insurance quotes are becoming more and more popular. ...
(Date:4/18/2015)... (PRWEB) April 18, 2015 "I recognized ... stretchers in healthcare facilities," said an inventor from Cincinnati, ... storage system." , He developed the Slyde Door to ... used in healthcare facilities. It provides convenient storage space ... are more stretchers available for patients. , This ...
(Date:4/18/2015)... 18, 2015 Review of Ophthalmology magazine ... ‘Strategies for Success’ program for cataract surgeons attending the ... San Diego, where eye surgeon Jeffrey L. Martin, MD ... event. Dr. Martin is the Managing Partner of North ... chose Dr. Martin to lead this year’s discussion on ...
(Date:4/18/2015)... Lowcostcarinsuranceprice.com has released a new blog ... auto insurance prices . , Drivers who ... theft may have to pay more for auto insurance ... policies can also offer protection against vehicle theft. ... online on a single website: http://lowcostcarinsuranceprice.com/ . ...
(Date:4/18/2015)... Patients who undergo radiation for a hematologic cancer ... but the disease is likely to differ in some ... Surviving Mesothelioma has just posted the details of this ... read it now. , Scientists from China, the ... who had both a hematologic cancer (like lymphoma or ...
Breaking Medicine News(10 mins):Health News:Auto Insurance Plans Are Cheaper During Spring! 2Health News:Dr. Jeffrey Martin Invited to Share Latest Breakthroughs in Cataract Care During Roundtable Discussion at National 2015 ASCRS Meeting In San Diego 2Health News:High Rates Of Car Theft Can Have An Impact on Auto Insurance Prices! 2Health News:New Study Examines Relationship Between Radiation for Hematologic Cancers and Development of Mesothelioma, According to Surviving Mesothelioma 2
... Corporation,("WorldHeart", Nasdaq: WHRT ), a pioneer in ... Alexander ("Alex") Martin as,President and CEO. Mr. Martin ... Mr. Martin joins WorldHeart from Edwards Lifesciences where ... Vice President since,2004. Previously, Alex was with Cordis ...
... Site Uses Search to Improve Point-of-Care Decisions ... leader in enterprise search, recently published a ... Platform(TM) helps health-care practitioners deliver faster and ... The case study details Vivisimo,s application for ...
... cancer risk almost 6-fold, researchers find , , FRIDAY, Feb. ... mutations that appear to predict a significant increased risk ... to early diagnosis and treatment, the researchers said. In ... and 1,590 deaths, according to the U.S. National Cancer ...
... University at Buffalo researcher John Violanti, Ph.D., a specialist ... a study on suicide risk among returning veterans. The ... number of soldiers taking their own lives., Violanti currently ... quickly persons associate feelings of self-harm, as a way ...
... Feb. 6 Masimo Corporation (Nasdaq: MASI ... and Low-Perfusion pulse oximetry, today announced that its management ... 21st Annual OC Growth Stock Conference at The Ritz-Carlton, ... 18, 2009, at 11:00 a.m. PT. A live audiocast ...
... Feb. 6 Optimal Reading Services Group, ... hospitals and radiology group practices, announced that its chief ... UBS Global Healthcare Services Conference on Monday, February 9, ... Hotel in New York City.Optimal leverages a deep pool ...
Cached Medicine News:Health News:WorldHeart Appoints New President and CEO 2Health News:WorldHeart Appoints New President and CEO 3Health News:New Vivisimo Case Study Details Medical Search 2Health News:Gene Test Could Predict Thyroid Cancer Risk 2Health News:Gene Test Could Predict Thyroid Cancer Risk 3Health News:Masimo to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference 2Health News:Optimal Readings to Present at 2009 UBS Global Healthcare Services Conference 2
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 8.0 mm and length 9 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 7.0 mm and length 8.7 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 9.0 mm and length 7.5 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 10.0 mm and length 12 mm....
Medicine Products: